@lsouceklab.bsky.social
Reposted
Link to the article: www.cell.com/cell-reports...
MYC inhibition by Omomyc causes DNA damage and overcomes PARPi resistance in breast cancer
Giuntini et al. demonstrate that Omomyc, the only direct MYC inhibitor currently in
phase 2 clinical trials, causes DNA damage and synergizes with PARPis in triple-negative
breast cancer. Their findin...
www.cell.com
December 3, 2025 at 6:56 AM
Link to the article: www.cell.com/cell-reports...
Reposted
Huge thanks to Fabio Giuntini, and to the entire teams at
@vhio.bsky.social and #peptomyc for making this possible. We also want to acknowledge the support of
#AECMM and the @erc.europa.eu for backing research that can make a real difference.
@vhio.bsky.social and #peptomyc for making this possible. We also want to acknowledge the support of
#AECMM and the @erc.europa.eu for backing research that can make a real difference.
December 3, 2025 at 6:56 AM
Huge thanks to Fabio Giuntini, and to the entire teams at
@vhio.bsky.social and #peptomyc for making this possible. We also want to acknowledge the support of
#AECMM and the @erc.europa.eu for backing research that can make a real difference.
@vhio.bsky.social and #peptomyc for making this possible. We also want to acknowledge the support of
#AECMM and the @erc.europa.eu for backing research that can make a real difference.
Reposted
In triple-negative breast cancer (TNBC), #Omomyc/#OMO-103 shuts down DNA-repair gene programs, triggers DNA damage and — in combination with PARP inhibitors — restores response even in PARPi-resistant models.
December 3, 2025 at 6:56 AM
In triple-negative breast cancer (TNBC), #Omomyc/#OMO-103 shuts down DNA-repair gene programs, triggers DNA damage and — in combination with PARP inhibitors — restores response even in PARPi-resistant models.